PubMed Health⌕ Search

Biomedical subjects

A U Okpara

Publications and source records attributed to A U Okpara.

4 recordsLinked to original sources

Enforcing a policy for restricting antimicrobial drug use.

An institution's experience in enforcing a policy for restricting the use of antimicrobial agents is described. A policy to restrict the use of eight intravenous antimicrobial agents had been in place for two years at a large county teaching hospital but had never been enforced. In 1994 an organized effort to enforce the policy was begun. Memorandums were sent to all medical staff, residents, pharmacists, and nurses informing them that the policy would be diligently enforced. Before a restricted antimicrobial could be dispensed, the approval of a physician specializing in infectious diseases was required. Under the direction of the pharmacy and therapeutics committee and an antimicrobial subcommittee, a specially hired team of pharmacists started to encourage more effective and economical prescribing of antimicrobials. During a nine-month period after enforcement began, use of the restricted antimicrobials declined, and use of nonrestricted antimicrobials increased. After two months, acquisition costs for the restricted drugs had been reduced by more than $82,000; however, a similar increase in acquisition costs for nonrestricted antimicrobials occurred. As a result, one nonrestricted agent was reclassified as restricted, and inservice sessions were held to teach prescribes about the appropriate use of another agent. In general, physicians were very compliant with the antimicrobial-restriction policy; the greatest resistance was encountered from surgical residents. Some-pharmacists needed warnings beyond the initial memorandum. Enforcement of an antimicrobial-restriction policy led to decreased use of the restricted drugs and substantial cost avoidance. As new patterns of antimicrobial use emerged, the restriction policy was modified as necessary.

Anti-Bacterial Agents↗

Criteria-based antimicrobial i.v. to oral conversion program.

Collaborative efforts among several departments and the P & T Committee resulted in an IV to oral conversion program for select antimicrobials in our 580-bed county teaching hospital. This criteria-based program was designed to monitor and educate physicians on the appropriateness of parenteral antimicrobial prescribing, ensure rapid transition from IV to oral therapy, and contain costs. In the first 2 months of the program, 78 patients were converted from IV to oral administration with an estimated savings of $12,935. Of the ordering physicians, 66 (84.6%) accepted the interventions. All patients who switched administration routes were successfully treated with an oral agent. This program also has had a positive effect on patient outcomes and physician prescribing habits.

Administration, Oral↗

Emergence of multidrug-resistant isolates of Acinetobacter baumannii.

Patterns of antimicrobial resistance during an outbreak of nosocomial infections caused by Acinetobacter baumannii were studied. The medical records of all patients admitted to the hospital between February 1993 and February 1994 from whom A. baumannii was cultured were reviewed for demographic data, confirmation of the isolation report, admission date, date of first isolation of the organism, and antimicrobial use before and after the culture and susceptibility test results were obtained. The culture and susceptibility test data were reviewed for all specimens submitted to the laboratory during the review period. A total of 87 patients (mean +/- S.D. age, 37.9 +/- 8.7 years) with nosocomial infection or colonization with A. baumannii were identified. All the patients were surgical intensive care unit residents and had predisposing factors for acinetobacter infection. A total of 107 isolates of the organism were cultured from various sites; sputum was the most common source. The number of isolates per month increased steadily beginning in September 1993 and then declined over the winter. The median time between admission and first isolation of resistant A. baumannii was 11 days. Infections were manifested clinically as pneumonia (36 patients), bacteremia (8), wound infection (6), and urinary-tract infection (2). Of the 107 isolates, all were resistant to formulary cephalosporins, extended-spectrum penicillins, quinolones, and aztreonam. Only nine isolates were susceptible to one or more aminoglycosides. All the isolates were susceptible to imipenem-cilastatin. During an outbreak of nosocomial infections with A. baumannii, all or nearly all of the 107 isolates were resistant to a broad range of antimicrobials with the exception of imipenem-cilastatin, to which all the isolates were susceptible.

Acinetobacter↗

Concurrent ceftazidime DUE with clinical pharmacy intervention.

Ceftazidime use at our institution, a 580-bed county teaching hospital, has steadily increased since its addition to the formulary in 1986. In response to this increased use and because the institutional antibiogram showed increased resistance by Pseudomonas aeruginosa (from 10 to 28% resistant), the P & T Committee requested that a drug use evaluation (DUE) of ceftazidime be conducted. Analysis of this retrospective pilot study showed that 87% of ceftazidime use was inappropriate. To further evaluate ceftazidime use, to identify problems not assessed during retrospective review, and to correct problems while patients were receiving the drug, a concurrent ceftazidime use evaluation was conducted. The methods and results of the concurrent review are presented below.

Ceftazidime↗